Adcendo ApS Receives FDA Fast Track Status for ADCE-D01 in Soft Tissue Sarcoma Treatment Adcendo ApS has been granted Fast Track designation by the FDA for ADCE-D01, aimed at treating soft tissue sarcoma, signaling a significant milestone in cancer therapy.

Adcendo ApS Receives FDA Fast Track Status for ADCE-D01 in Soft Tissue Sarcoma Treatment #Denmark #Copenhagen #Adcendo_ApS #ADCE-D01 #soft_tissue_sarcoma

Adcendo ApS Receives FDA's Fast Track Designation for ADCE-D01 in Soft Tissue Sarcoma Treatment Adcendo ApS has announced that its ADCE-D01 drug candidate has received Fast Track designation from the FDA, aimed at treating soft tissue sarcoma effectively.

Adcendo ApS Receives FDA's Fast Track Designation for ADCE-D01 in Soft Tissue Sarcoma Treatment #FDA #Denmark #Copenhagen #Adcendo_ApS #ADCE-D01

Adcendo ApS to Share Insights on Clinical ADC Developments at 2025 AACR Annual Meeting Adcendo ApS is set to present its innovative ADC therapies ADCE-T02 and ADCE-D01 at the upcoming AACR Annual Meeting, showcasing promising clinical advancements.

Adcendo ApS to Share Insights on Clinical ADC Developments at 2025 AACR Annual Meeting #Denmark #Copenhagen #Adcendo_ApS #ADCs #AACR_2025

Duality Biologics and Adcendo ApS Strengthen Collaborative Efforts for Cancer Treatment Advancements Duality Biologics has expanded its collaboration with Adcendo ApS to enhance their groundbreaking antibody-drug conjugate (ADC) pipeline, focusing on novel treatments for cancer.

Duality Biologics and Adcendo ApS Strengthen Collaborative Efforts for Cancer Treatment Advancements #United_States #Duality_Biologics #Adcendo_ApS #antibody-drug_conjugate #Princeton